A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer.
Ian KropVandana G AbramsonMarco ColleoniTiffany TrainaFrankie Ann HolmesLaura Garcia-EstevezLowell HartAhmad AwadaClaudio ZamagniPatrick G MorrisLee SchwartzbergStephen ChanAyca GucalpLaura BiganzoliJoyce SteinbergLorenzo SicaMaureen TrudeauDenka MarkovaJamal C TaraziZhou ZhuThomas O'BrienCatherine M KellyEric P WinerDenise A YardleyPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Enzalutamide with exemestane was well tolerated. While PFS was not improved by the addition of enzalutamide to exemestane in an unselected population, ET-naïve patients with high AR mRNA levels, particularly in combination with low ESR1 mRNA levels, may benefit from enzalutamide with exemestane.